<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299389</url>
  </required_header>
  <id_info>
    <org_study_id>CR017026</org_study_id>
    <secondary_id>PALM-JPN-4</secondary_id>
    <nct_id>NCT01299389</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as
      compared with placebo in the treatment of participants with schizophrenia (psychiatric
      disorder with symptoms of emotional instability, detachment from reality, often with
      delusions [a false belief held in the face of strong differing evidence, especially as a
      symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into
      the self).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study drug is assigned by chance), double-blind (neither physician
      nor participant knows the name of the assigned drug), placebo-controlled (an inactive
      substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with
      a drug to test if the drug has a real effect), parallel-group (comparing the response in two
      groups of participants receiving different treatments), fixed-dose, multi-center (when more
      than one hospital or medical school team work on a medical research study) study of
      paliperidone palmitate in participants with schizophrenia. The study will consist of 3
      periods: an up to 2-week pre-observation (screening) period, a double-blind period from Day 1
      (baseline) to Week 13 (end of double-blind period) assessment, and a post-observation period
      starting after the Week 13 assessment to Week 21. For participants who discontinue the study
      before the last assessment in Week 13, the post-observation period will start after the
      discontinuation from double-blind period assessment with follow-up visits at 4, 8, and 12
      weeks after the last injection. After completion of the double-blind period (Week 13),
      discontinuation of double-blind period treatment or withdrawal from the study, participants
      may receive treatment consistent with the usual standard of care. The total duration of the
      study will be 21 weeks, including the double-blind and post-observation periods. Participants
      will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio (intramuscular injections
      of either paliperidone palmitate or matching placebo). Injections of paliperidone palmitate
      or placebo will be given at Day 1 and at Weeks 1, 5, and 9 by a study drug manager and/or
      injector. For those participants receiving paliperidone palmitate, the Day 1 injection will
      be 150 milligram equivalent (mg eq.) paliperidone palmitate, followed by 100 mg eq.
      injections of paliperidone palmitate at Week 1, and 75 mg eq. injections of paliperidone
      palmitate at Weeks 5 and 9. Participants randomly assigned to placebo will receive injections
      matching the paliperidone palmitate injections on the same days. Efficacy will be assessed
      using Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression - Severity
      (CGI-S). Participant's safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
    <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
    <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill participants&quot;, higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Response to the Treatment as Per PANSS Total Score.</measure>
    <time_frame>up to Week 13 or early discontinuation</time_frame>
    <description>Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation (ED)</time_frame>
    <description>The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
    <description>Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
    <description>Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation</measure>
    <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
    <description>General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone palmitate</intervention_name>
    <description>Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.</description>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants meeting Diagnostic criteria for schizophrenia according to Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition Text Revision

          -  Women had to be: postmenopausal (for at least 2 years), surgically sterile (had a
             hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of
             pregnancy), abstinent (as judged by the investigator; per local regulations), or if
             sexually active, be practicing a highly effective method of birth control (eg,
             prescription oral contraceptives, contraceptive injections, contraceptive patch,
             intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap,
             with spermicidal foam, cream, or gel], male partner sterilization) as local
             regulations permitted, before entry, and had to agree to continue to use the same
             method of contraception throughout the study

          -  A Positive and Negative Syndrome Scale (PANSS) total score at screening and at
             baseline (Day 1) of 60 to 120

          -  Documented history of exposure to either a risperidone formulation or a paliperidone
             formulation and known to be tolerated before baseline (Day 1) (Even if the
             participant's experience of taking risperidone or paliperidone cannot be confirmed at
             the time of informed consent, the participant will be able to meet this criterion if
             the participant takes oral risperidone 2 mg/day or more or paliperidone ER 6 mg/day or
             more for at least 4 days between the day of informed consent and the day before
             baseline, and it is possible to confirm that there is no lack of tolerability in the
             participant)

          -  Women of childbearing potential must have a negative beta human chorionic gonadotropin
             pregnancy test at the screening urine pregnancy test

        Exclusion Criteria:

          -  Primary active Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
             Text Revision Axis I diagnosis other than schizophrenia

          -  A Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision
             diagnosis of active substance dependence within 3 months before screening (nicotine
             and caffeine are not exclusionary)

          -  Relevant history or current presence of any significant or unstable cardiovascular,
             respiratory, neurological (including seizures or significant cerebrovascular), renal,
             hepatic, hematologic, endocrine, immunologic, or other systemic disease

          -  History or current presence of neuroleptic malignant syndrome or tardive dyskinesia

          -  Known or suspected hypersensitivity or intolerance to risperidone, paliperidone,
             Intralipid, or any of their excipients (including egg yolks, soybean oil,
             phospholipids, and glycerol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fujioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ichikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itoman</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanzaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasuya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitagunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koshigaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumagaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurayoshi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kure</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohta</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oyabe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamana</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyoake</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urasoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yatsushiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokkaichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungcheongbuk-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deajun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inchun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bali Township, Taipei County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hua Lian</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>March 4, 2013</results_first_submitted>
  <results_first_submitted_qc>June 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2013</results_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paliperidone palmitate</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Double-blind)</title>
          <description>Matching Placebo was given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64.</description>
        </group>
        <group group_id="P2">
          <title>Paliperidone Palmitate (Double-blind)</title>
          <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Post-observational)</title>
          <description>Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
        <group group_id="P4">
          <title>Paliperidone Palmitate (Post-observational)</title>
          <description>Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>fail to meet “study population” criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-observational</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all randomly assigned participants who received at least 1 injection of double-blind study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Double-blind)</title>
          <description>Matching Placebo was given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
        <group group_id="B2">
          <title>Paliperidone Palmitate (Double-blind)</title>
          <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="159"/>
            <count group_id="B3" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="12.41"/>
                    <measurement group_id="B2" value="45.7" spread="13.55"/>
                    <measurement group_id="B3" value="44.8" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation</title>
        <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.</description>
        <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
        <population>Full Analysis Set (FAS) population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. Last Observation Carried Forward (LOCF) method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularl (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation</title>
          <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.</description>
          <population>Full Analysis Set (FAS) population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. Last Observation Carried Forward (LOCF) method was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="15.18"/>
                    <measurement group_id="O2" value="85.7" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13 or Early Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="19.13"/>
                    <measurement group_id="O2" value="-3.1" spread="20.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 13 or Early Discontinuation: P value were calculated using an analysis of covariance (ANCOVA) model with treatment and country as factors and baseline PANSS total score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares (LS) means difference</param_type>
            <param_value>-9.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>-5.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation</title>
        <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill participants&quot;, higher scores indicate worsening.</description>
        <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation</title>
          <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill participants&quot;, higher scores indicate worsening.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13 or Early Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Response to the Treatment as Per PANSS Total Score.</title>
        <description>Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.</description>
        <time_frame>up to Week 13 or early discontinuation</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Response to the Treatment as Per PANSS Total Score.</title>
          <description>Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than or equal to 30 percent Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 20 percent Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation</title>
        <description>The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.</description>
        <time_frame>Baseline and Week 13 or early discontinuation (ED)</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation</title>
          <description>The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive symptoms: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="5.56"/>
                    <measurement group_id="O2" value="24.2" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive symptoms: Change at Week 13 or ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="6.06"/>
                    <measurement group_id="O2" value="-1.1" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative symptoms: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="6.22"/>
                    <measurement group_id="O2" value="22.8" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative symptoms: Change at Week 13 or ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.82"/>
                    <measurement group_id="O2" value="-1.4" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disorganized thoughts: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="5.13"/>
                    <measurement group_id="O2" value="20.8" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disorganized thoughts: Change at Week 13 or ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="5.24"/>
                    <measurement group_id="O2" value="-0.6" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncontrolled hostility/excitement: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.07"/>
                    <measurement group_id="O2" value="8.6" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncontrolled hostility: Change at Week 13 or ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.23"/>
                    <measurement group_id="O2" value="0.4" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="3.02"/>
                    <measurement group_id="O2" value="9.4" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression: Change at Week 13 or ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.27"/>
                    <measurement group_id="O2" value="-0.4" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Positive symptoms (change at Week 13 or ED): P value was calculated using an ANCOVA model with treatment and country as factors and baseline PANSS factor scores as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Negative symptoms (change at Week 13 or ED): P value was calculated using an ANCOVA model with treatment and country as factors and baseline PANSS factor scores as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Disorganized thoughts (change at Week 13 or ED): P value was calculated using an ANCOVA model with treatment and country as factors and baseline PANSS factor scores as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Uncontrolled hostility/excitement (change at Week 13 or ED): P value was calculated using an ANCOVA model with treatment and country as factors and baseline PANSS factor scores as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anxiety/depression (change at Week 13 or ED): P value was calculated using an ANCOVA model with treatment and country as factors and baseline PANSS factor scores as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation</title>
        <description>Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.</description>
        <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation</title>
          <description>Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="6.19"/>
                    <measurement group_id="O2" value="24.0" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13 or Early Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.54"/>
                    <measurement group_id="O2" value="-1.5" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 13 or Early Discontinuation: P value were calculated using an ANCOVA model with treatment and country as factors and baseline PANSS total score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation</title>
        <description>Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.</description>
        <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation</title>
          <description>Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="4.97"/>
                    <measurement group_id="O2" value="19.5" spread="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13 or Early Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.82"/>
                    <measurement group_id="O2" value="-0.6" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 13 or Early Discontinuation: P value were calculated using an ANCOVA model with treatment and country as factors and baseline PANSS total score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation</title>
        <description>General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.</description>
        <time_frame>Baseline and Week 13 or early discontinuation</time_frame>
        <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Double-blind)</title>
            <description>Matching Placebo was given intramuscularly on Day 1, Day 8, Day 36 and Day 64.</description>
          </group>
          <group group_id="O2">
            <title>Paliperidone Palmitate (Double-blind)</title>
            <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation</title>
          <description>General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.</description>
          <population>FAS population included all randomly assigned participants who received at least 1 injection of double-blind study drug and had baseline and at least 1 post-baseline PANSS total scores. LOCF method was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="7.97"/>
                    <measurement group_id="O2" value="42.3" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 13 or Early Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="10.32"/>
                    <measurement group_id="O2" value="-1.0" spread="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 13 or Early Discontinuation: P value were calculated using an ANCOVA model with treatment and country as factors and baseline PANSS total score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of the informed consent until study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Double-blind)</title>
          <description>Matching Placebo was given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64.</description>
        </group>
        <group group_id="E2">
          <title>Paliperidone Palmitate (Double-blind)</title>
          <description>Paliperidone palmitate was given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Post-observational)</title>
          <description>Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
        <group group_id="E4">
          <title>Paliperidone Palmitate (Post-0bservational)</title>
          <description>Participants who completed double-blind period or discontinued early from double-blind period had follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants did not receive any study drug during post-observational period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Auricular swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oculogyric crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lip haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Adenoviral conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Superficial injury of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urobilinogen urine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lymphocyte percentage decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diet refusal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Weight fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nuchal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sleep phase rhythm disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Head titubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thermohyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tardive dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysstasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Persecutory delusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Inappropriate affect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Obsessive thoughts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Soliloquy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Somatic delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Impulse-control disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin chapped</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical director</name_or_title>
      <organization>Janssen Pharmaceutical K.K</organization>
      <phone>+81-3-4411-5509</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

